

Emily Knight, PhT

eknight@preferredresearchpartners.com

Ph: 501-553-9987 x117

Research Affiliations

Offices

Preferred Research Partners, Inc.

11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Preferred Research Partners Arkansas Center for Sleep Medicine

11219 Financial Center Parkway, Suite 101
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

EDUCATION

Certificate in Pharmacy Technician

Arkansas State University Beebe - Beebe, AR
Graduation date: December 2014

Associate's in Associate of Liberal Arts

Arkansas State University Beebe - Beebe, AR
Graduation date: May 2012

WORK EXPERIENCE

January 2020 – present

Preferred Research Partners – Clinical Research Coordinator - Little Rock, AR

Position involved conducting study visits & ensuring patient safety, AE/SAE reporting, facilitating informed consent process, collection of IRB correspondence, patient recruitment, pre-screening, CRF and source documentation completion, VS, ECG & other protocol related procedures.

August 2019 – January 2020

Preferred Research Partners, Inc. – Clinical Research Assistant – Little Rock, AR

Primary Duties: Screening potential subjects for ongoing trials. Maintaining accurate patient info, administration of patient questionnaires, performing EKG, vital signs, phlebotomy & laboratory processing for trial participants. Coordinating patient schedules. Working closely with principal investigators and study coordinators to ensure compliance and safety measures achieved. Collect adverse event data, administer investigational drug, data entry. Accurate and timely reporting of any serious adverse events to IRB and Sponsor. Knowledge of FDA guidelines. Prescreening, database entry & portal updates.

January 2015 - August 2019

Fred's Pharmacy - Pharmacy Technician - Beebe, AR

- Answer telephone calls regarding customer accounts.
- Consult with customers to evaluate needs and determine best options.
- Protects patients and employees by adhering to infection-control policies and protocols.
- Helps health care providers and patients by greeting them in person and by phone; answering questions and requests; referring inquiries to the pharmacist.
- Ability to perform pharmaceutical calculations relating to drug quantities and dosages.
- Maintains pharmacy inventory by checking pharmaceutical stock to determine inventory level; anticipating needed medications and supplies; placing and expediting orders; verifying receipt; removing outdated drugs.
- Able to interpret prescriptions, count medications, and work with customers to meet their medication needs.
- Knowledgeable in pharmacy practices, pharmaceutical rules, procedures, regulations, and operations to perform a variety of complex technical functions.
- Maintains a safe and clean pharmacy by complying with procedures, rules, and regulations. Knowledge of standard procedures and techniques.
- Organizes medications for pharmacist to dispense by reading medication orders and prescriptions; preparing labels; calculating quantities; assembling

Clinical Research Experience

Pharmaceutical:

- 2018: Ironwood Pharmaceuticals – GERD – C3718-302
- 2019: Tonix Pharmaceuticals - PTSD – TNX-CY-P302
- 2019: Apnimed – Obstructive Sleep Apnea – APN-002
- 2019: Aptinyx – Post-Traumatic Stress Disorder – NYX-783-2004
- 2019: Axsome Pharmaceuticals – Treatment-Resistant Depression – AXS05-301
- 2019: Biohaven Pharmaceuticals – Obsessive Compulsive Disorder – BHV4157-202
- 2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071

- 2019: Takeda – Obstructive Sleep Apnea – Phase 1 – TAK-925-2001
- 2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002
- 2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure) – AT-001-2001
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003
- 2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64
- 2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66
- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270
- 2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002
- 2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201
- 2020: Otsuka – Pediatric Attention Deficit Hyperactivity Disorder – 405-201-00010
- 2020: Apnimed – Obstructive Sleep Apnea – APN-006
- 2020: Janssen – Treatment-resistant Depression – 54135419TRD4005
- 2020: Janssen – Major Depression & Insomnia – 42847922MDD3002
- 2020: Novavax – COVID-19 Vaccine – 2019nCoV-301
- 2020: Supernus – ADHD in Preschoolers – 812P401
- 2020: GlaxoSmithKline – Meningococcal B Vaccine - 205416
- 2021: Otsuka Pharmaceuticals – ADHD in Children – 405-201-00046
- 2021: Apnimed – Obstructive Sleep Apnea – APC-003
- 2021: Apnimed – Obstructive Sleep Apnea – APC-003-OLE
- 2021: Moderna – CMV Vaccine – mRNA-1647-P301
- 2021: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-201
- 2021: Acerus Pharmaceuticals – Ambulatory BP monitoring in Hypogonadism – NAT-2020-01
- 2021: Purdue Pharma LP – ADHD in Preschoolers & Children – ADA4004
- 2021: BlackThorn – MDD with Anhedonia &/or GAD – K2-MDD-201
- 2021: Relmada – Major Depressive Disorder – REL-1017-302
- 2021: Relmada – Major Depressive Disorder – REL-1017-310
- 2021: AbbVie – Pediatric Migraine - 3110-305-002
- 2021: AbbVie – Pediatric Migraine – 3110-306-002
- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00016
- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00017

- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00021
- 2021: Revolo Pharmaceuticals – Eosinophilic Esophagitis – RVLO 121-04
- 2021: Eliem Therapeutics – MDD in Perimenopausal Females – ETX-020155-202
- 2022: Mind Med – Generalized Anxiety Disorder – MMED008
- 2022: Merck – Treatment Resistant Depression – MK1942-006
- 2022: 89 Bio – NASH – BIO89-100-122
- 2022: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-301
- 2022: Alto Neurosciences – PTSD &/or MDD – ALTO-100-001
- 2022: Braintree Laboratories – Erosive Esophagitis – BLI5100-301
- 2022: Braintree Laboratories – Non-erosive Reflux Disease – BLI5100-302
- 2022: Ellodi Pharmaceuticals, L.P. – Eosinophilic Esophagitis – SP-1011-005
- 2022: Hepion Pharmaceuticals. – Non-alcoholic Steatohepatitis – HEPA-CRV431-207
- 2022: Idorsia Pharmaceuticals, Inc. – Pediatric Insomnia – ID-078A205
- 2022: Janssen – Bipolar Depression – 55308942BIP2001
- 2022: Merck – HPV Vaccine & mRNA COVID-19 Vaccine in 9-11 y/o – V503-076
- 2022: Novavax – Pediatric COVID-19 Vaccine – 2019nCoV-503
- 2022: Perception Neuroscience, Inc. – Treatment Resistant Depression – PCN-101-21
- 2022: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-102
- 2022: Supernus Pharmaceuticals – Child & Adolescent ADHD – 812P412
- 2023: Alto Neurosciences – MDD – ALTO-100-201
- 2023: AbbVie – Pediatric Episodic Migraine – M21-199
- 2023: AbbVie – Pediatric Episodic Migraine – M21-201
- 2023: Corium – Pediatric ADHD in ages 4-12 y/o – KP415.P01
- 2023: Corium – Pediatric ADHD – KP415.P02
- 2023: CinDome – Adult Diabetic Gastroparesis – CIN-102-123
- 2023: Tonix – Adult Major Depressive Disorder – TNX-TI-M201
- 2023: Tonix- Adult Chronic Migraine – TNX-OX-CM201
- 2023: Braintree Laboratories – Gastroesophageal Reflux Disease – BLI5100-303
- 2023: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-103
- 2023: Shionogi – COVID-19 & prevention in household contacts – 226T1331
- 2023: Apnimed – Sleep Apnea – APC-APN-304
- 2023: Lilly – Diabetic Peripheral Neuropathy Pain – J2P-MD-LXBD
- 2023: Supernus – Pre-schooler ADHD – 812P310
- 2023: Supernus / Navitor – Treatment Resistant Major Depressive Disorder – NAV-17A-007
- 2023: Bayer – Sleep Disturbances Associated with Menopause – 22423 (NIRVANA)
- 2023: Usona – Major Depressive Disorder – PSIL301
- 2024: Axsome – Major Depressive Disorder – SOL-MDD-301
- 2024: Axsome – Excessive Daytime Sleepiness with Shift Work Disorder – SOL-SWD-301
- 2024: Axsome – Major Depressive Disorder in Children & Adolescents – AXS-05-MDD-402
- 2024: Axsome – Major Depressive Disorder in Children & Adolescents (extension) – AXS-05-MDD-403
- 2024: AbbVie – Menstrual Migraine Prevention – M23-714
- 2024: Apnimed – Obstructive Sleep Apnea – APC-APN-305

- 2024: MindMed – Generalized Anxiety Disorder – MM120-300/301
- 2024: Apnimed – Obstructive Sleep Apnea – APC-APN-306
- 2024: Vistagen – Social Anxiety Disorder – PH94B-CL042 (PALISADE-3)
- 2024: Vanda – Diabetic & Idiopathic Gastroparesis – VP-VLY-686-3303
- 2024: Phathom – Eosinophilic Esophagitis – EoE-201
- 2024: Phathom – Pediatric GERD – VPED-104
- 2024: Alkermes – Narcolepsy – ALKS2680-202
- 2024: Neumora – Major Depressive Disorder – NMRA-335140-301
- 2024: Neumora – Major Depressive Disorder – NMRA-335140-501
- 2024: AbbVie – Migraine Prevention in Adults – M24-873
- 2024: Lilly – Chronic Weight Management & Obstructive Sleep Apnea – J1I-MC-GZBK/GSA2
- 2024: Alto Neuroscience – Bipolar Depression – ALTP-100-211
- 2024: VistaGen Therapeutics, Inc. - Social Anxiety Disorder (PALISADE-4) - PH94B-CL043
- 2024: Janssen (J&J) – Adjunctive Treatment for Relapse Prevention in Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia – 67953964MDD3005 (VENTURA-5)
- 2024: Janssen – Adjunctive Therapy in Adult & Elderly Major Depressive Disorder (MDD) with Insomnia - 42847922MDD3003 (OARS-7)
- 2025: Cindome Pharma, Inc. - Idiopathic Gastroparesis – CIN-102-124
- 2025: Phathom Pharmaceuticals, Inc.- Eosinophilic Esophagitis (EoE) – EoE-201
- 2025: Eli Lilly & Company - Moderately to Severely Active Ulcerative Colitis – I7J-MC-DSAG
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Ulcerative Colitis – EFC18325
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Crohn’s Disease – EFC18326
- 2025: Sanofi-Aventis - Maintenance study - Moderately to Severely Active Crohn’s Disease – EFC18327
- 2025: Sanofi-Aventis - Maintenance Study - Moderately to Severely Active Ulcerative Colitis – EFC18359
- 2025: Mirador Therapeutics, Inc. - Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD) – MT-100-201/PROBEUC/PROBECD
- 2025: Orion Corporation - Insomnia – 3110012
- 2025: Mind Medicine, Inc. – Major Depressive Disorder (MDD) – MM123-310 (EMERGE)
- 2025: Atai Pharmaceuticals – Treatment Resistant Depression (TRD) – VLS-01-203
- 2025: AbbVie – Pediatric Chronic Migraine ages 12-17 y/o – M23-712
- 2025: Alkermes – Idiopathic Hypersomnia – ALKS2680-203
- 2025: Alkermes – Narcolepsy – ALKS2680-301
- 2025: Mineralys Therapeutics, Inc. – Moderate to Severe Sleep Apnea (OSA) – MLS-101-207
- 2025: Transcend Therapeutics – Post-Traumatic Stress Disorder (PTSD) - TSND201-PTSD-301
- 2025: Axsome Therapeutics – Fibromyalgia – AXS-14-FM-301

Other:

2019: Guardant Health - Evaluation of ctDNA LUNAR-2 Assay in an Average Patient Screening Episode – 02-GI-002

Training

- August 2019 CITI Principal Investigators, Co-Investigators & Research Staff training
- August 2019 HIPAA & Clinical Trials training
- August 2019 CITI Good Clinical Practice training
- August 2019 GCP Manual/Code of Federal Regulations Review
 - Phlebotomy Training
 - Informed Consent Training
 - Vital Signs Training
 - EKG Training
 - Job Shadowing
 - Blood Borne Pathogen Training
 - SOP Manual Review and Sign-Off
 - HIPAA Training
- August 2021 Mayo Clinic-IATA and Transporting Dangerous Goods
- June 2022 CITI Good Clinical Practice training
- July 2023 Mayo Clinic-IATA and Transporting Dangerous Goods
- June 2024 CITI Good Clinical Practice training